908 Devices (MASS) Stifel 2024 Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Stifel 2024 Healthcare Conference summary
13 Jan, 2026Business overview and growth drivers
Focus on point-of-need chemical detection, expanding lab-grade tools beyond central labs, with a strong forensic franchise making up about 75% of revenues and 2,700 handheld devices deployed.
Bioprocessing/biopharma desktop devices have faced macro headwinds but are supported by five articulated growth drivers and cost structure improvements, including RedWave Technology acquisition.
Handhelds have grown at a 27% CAGR from 2018–2023, with recent years above 14% CAGR, despite government budget delays causing sales lumpiness.
Portfolio expansion from one to four handheld products and increased international and state/local sales help balance revenue volatility.
Reference customers, such as the U.S. Army, have aided in expanding enterprise accounts.
RedWave acquisition and product synergies
RedWave brings FTIR technology, complementing mass spec handhelds, expanding analyte detection to 22,000 in bulk and 5,000 gases.
Sales and applications teams are well-positioned to integrate RedWave products, leveraging existing training and commercial infrastructure.
Identified $7.5 million in cost and revenue synergies, with RedWave's state/local presence and new federal/international opportunities.
Cross-selling is already occurring, with bundled deals and broader customer engagement.
RedWave's trajectory is expected to match historical handheld growth rates.
Market expansion and untapped applications
FTIR and mass spec technologies are applicable to diagnostics, food, air, water, forensics, and bioprocessing.
XplorIR, a RedWave product, enables detection of 5,000 gases, broadening applications to environmental and hazmat markets.
Year-to-date shipments of XplorIR have doubled compared to the previous year.
International enterprise accounts are growing, with the largest APAC order shipped in October and expansion in the Middle East and Europe.
Diversification across products and markets helps mitigate reliance on large enterprise accounts.
Latest events from 908 Devices
- Transformation and innovation in handheld detection devices drive strong growth and profitability.MASS
Sidoti March Small-Cap Virtual Conference18 Mar 2026 - Strong growth, innovation, and global expansion set the stage for profitability by 2027.MASS
Leerink Global Healthcare Conference 20269 Mar 2026 - Up to $100 million in securities to fund growth in handheld chemical analysis markets.MASS
Registration Filing9 Mar 2026 - Handheld detection tools, new products, and software drive growth and recurring revenue in 2026.MASS
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - 2025 revenue rose 18% to $56.2M, margins hit 57%, and Q4 Adjusted EBITDA turned positive.MASS
Q4 20253 Mar 2026 - Q2 revenue up 16% to $14M; 2024 outlook reaffirmed at $63–$65M, with strong handheld growth.MASS
Q2 20242 Feb 2026 - Handheld growth, RedWave integration, and innovation set the stage for future acceleration.MASS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - RedWave acquisition and product innovation drive growth, margin gains, and market expansion.MASS
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Q3 revenue up 17%, but net loss widened on goodwill impairment and RedWave acquisition costs.MASS
Q3 202415 Jan 2026